In pharmacy news:

The FDA has accepted the filing of a new drug application for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes, a common comorbidity which complicates workers’ comp claims. Empagliflozin is a sodium glucose co-transporter-2 (SGLT2) inhibitor, which removes excess glucose through the urine by blocking glucose reabsorption in the kidney. Metformin, a commonly prescribed initial treatment for type 2 diabetes, decreases the production of glucose in the liver and its absorption in the intestine and improves the body’s ability to utilize glucose.

Read a full overview of the filing here.

Leave a Comment

Your email address will not be published. Required fields are marked *